Practice overview

Solutions

Health Care

Fueled by increasing consumer income, population aging, and government initiatives, China's health care market is growing rapidly, with annual expenditures projected to reach $896.7 billion by 2019, up from an estimated $579.7 billion in 2014.  

Deloitte China Health Care practice

Deloitte China Life Sciences and Health Care team provides audit, tax, financial advisory services, consulting services and enterprise risk services for health care providers, including hospitals, professional service providers, outpatient facilities and long term care. Kennedy recently ranks Deloitte as the #1 Global Health Care Consulting practice.

Featured publications

  • Internet Hospitals in China: The new step into digital healthcare
    This report examines how internet hospitals thrive under the 2030 Health China Planning Outline and COVID-19, and puts forward six issues and solutions for internet hospitals and with giving a panorama of it.
  • 2021 Global Health Care Outlook: Accelerating industry change
    The report looks at six issues driving change in the health care sector and present questions and actions health leaders should consider in the coming year. How stakeholders analyze, understand, and respond to these issues will shape their ability to navigate from recovering to thriving in the post-pandemic “new normal” and advance their journey along the path to the Future of Health.
  • China Aesthetic Medicine Market Outlook Report
    The report examined the different aspects of China's aesthetic medicine industry, including consumer demand, value chains, marketing approaches, and financing sources. The report also reveals five prevailing trends that will drive industry development, with "light" aesthetic medicine becoming a strategic focus. Regulatory reform and reshuffling are set to reshape the market landscape by raising quality and practice standards, as the sector enters a mature phase of development.
  • Six predictions for China's pharma & healthcare sector
    The coronavirus outbreak will likely lead to profound changes to the dynamics of China healthcare industry. These changes could include massive investment in disease prevention infrastructure, the accelerated digital transformation of healthcare delivery models, a re-visiting of pharmaceutical companies pipeline strategies, as well as the adoption of advanced technology healthcare solutions. Deloitte makes six predictions in the report and sets out the implications for industry players.
  • COVID-19: Pharma Industry Survey Results
    With the breakout of COVID-19, Deloitte China Life Sciences & Health Care Industry team initiated a survey to understand the virus impact on China pharmaceutical industry and measure the longer-term impact this could eventually have on their business model and operating processes. We hope this report supports your business decisions during this special period.
  • 2020 China Life Sciences and Health Care M&A Trends
    The report based on deal data, delves into uncertainties and challenges in M&A activities, especially M&A trends in subsectors such as drugs, biotech, medical service institutions and medical device manufacturers.